{"gene":"HLA-G","run_date":"2026-06-10T01:55:22","timeline":{"discoveries":[{"year":1994,"finding":"HLA-G expression on trophoblast cells confers resistance to lysis by decidual NK cells. HLA-G transfectants of HLA-null LCL 721.221 cells were protected from NK effectors isolated from decidua or peripheral blood, demonstrating that a nonclassical Class I HLA molecule provides NK resistance.","method":"NK cytotoxicity assay using HLA-G transfectants of HLA-null LCL 721.221 cells","journal":"Cellular immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct functional transfection experiment with cytotoxicity readout, single lab but clear mechanistic demonstration","pmids":["8181068"],"is_preprint":false},{"year":1996,"finding":"IFN-γ selectively induces HLA-G expression in mononuclear phagocytes (macrophage cell lines and blood monocytes) at both mRNA and protein levels, increasing cell-surface and intracellular HLA-G in a dose-dependent manner, whereas IFN-α and IFN-β are poor inducers of cell-surface HLA-G protein.","method":"Northern blot hybridization, RT-PCR, immunohistochemistry, flow cytometry on macrophage cell lines (U937, HL-60, THP-1) and blood monocytes treated with interferons","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (RT-PCR, Northern blot, flow cytometry), single lab","pmids":["8666791"],"is_preprint":false},{"year":1997,"finding":"HLA-G undergoes severely impaired spontaneous endocytosis compared to classical MHC class I proteins, attributable to its short cytoplasmic tail. Chimeric proteins with HLA-C extracellular domains fused to the HLA-G C-terminal sequence, or GPI-tailed HLA-C proteins, were also not efficiently internalized, confirming the cytoplasmic tail as the determinant.","method":"Flow cytometry-based endocytosis assay using antibody-labeled transfectants; mutant β2-microglobulin (Ser88Cys) fluorescent-label exchange method to track internalization non-perturbatively","journal":"European journal of immunology","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple orthogonal methods including a non-perturbative fluorescent label exchange approach, chimeric protein controls directly attributing phenotype to cytoplasmic tail","pmids":["9368631"],"is_preprint":false},{"year":1999,"finding":"HLA-G inhibits NK cell cytolysis and T cell allogeneic proliferative and antigen-specific CTL responses. Membrane-bound HLA-G1 and HLA-G2 transfected cells, as well as full-length soluble HLA-G, were shown to impair NK and T cell functions in vitro.","method":"In vitro NK cytotoxicity assays and T cell allogeneic proliferation/CTL assays using HLA-G1- and HLA-G2-transfected cells and soluble HLA-G protein","journal":"Seminars in cancer biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct functional assays with transfected cells and soluble protein, single lab, multiple immune cell types tested","pmids":["10092545"],"is_preprint":false},{"year":1999,"finding":"HLA-G expressed on melanoma cells inhibits NK cell cytolysis. HLA-G-positive melanoma cell lines inhibited lysis by the NK cell line YT2C2-PR, and this inhibition occurred through interaction with inhibitory receptors distinct from known KIRs recognizing HLA-E or classical class I molecules.","method":"RT-PCR for HLA-G transcripts in melanoma cell lines and biopsies; NK cytotoxicity assay using YT2C2-PR NK cells against HLA-G-positive melanoma lines","journal":"Journal of reproductive immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct NK cytotoxicity assay with natural HLA-G-expressing tumor cells, single lab","pmids":["10479054"],"is_preprint":false},{"year":2000,"finding":"IFN-γ re-induces HLA-G cell surface expression and upregulates HLA-G transcripts in primary thymic epithelial cell (TEC) and amnion epithelial cell cultures, demonstrating that IFN-γ induction is mediated at the transcriptional level in these tissues.","method":"Flow cytometry for HLA-G surface expression; RT-PCR for HLA-G transcripts in primary thymic and amnion epithelial cell cultures treated with IFN-γ","journal":"Human immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple methods (flow cytometry, RT-PCR) in primary cell cultures, single lab","pmids":["11137212"],"is_preprint":false},{"year":2001,"finding":"The HLA-G promoter lacks the ISRE element and contains modified enhancer A and SXY modules, rendering it unresponsive to NF-κB, IRF1, and class II transactivator (CIITA) DNA-binding factors, explaining its restricted tissue-specific expression.","method":"Promoter sequence analysis; transgenic HLA-G mouse models with in situ hybridization and RT-PCR to assess constitutive placental expression","journal":"Immunogenetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional promoter dissection with transgenic mouse in vivo validation, single lab analysis","pmids":["11797094"],"is_preprint":false},{"year":2002,"finding":"Membrane-bound HLA-G1 and soluble HLA-G5 both require peptide association for cell surface expression, utilizing TAP-dependent or TAP-independent pathways. Peptide loading plays a critical role in controlling the quality of HLA-G molecules reaching the cell surface. Surface expression of truncated HLA-G isoforms is also possible.","method":"Biochemical trafficking studies and analysis of viral immune escape strategies (US proteins); biochemical fractionation and protein expression analysis","journal":"Cellular and molecular life sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — biochemical characterization of intracellular trafficking using viral escape mutants as tools, single lab","pmids":["12440768"],"is_preprint":false},{"year":2003,"finding":"HLA-G gene repression is mediated by DNA methylation of CpG sites in its 5' regulatory region. Treatment of HLA-G-negative cell lines with histone deacetylase inhibitors or the demethylating agent 5-aza-2'-deoxycytidine reverses this repression and can directly induce HLA-G cell-surface expression.","method":"Pharmacological demethylation (5-aza-2'-deoxycytidine) and histone deacetylase inhibitor treatment of seven HLA-G-negative cell lines; RT-PCR and flow cytometry for HLA-G expression","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — mechanistic epigenetic experiment with two orthogonal pharmacological approaches across multiple cell lines, direct functional readout of cell-surface expression","pmids":["12552087"],"is_preprint":false},{"year":2003,"finding":"HLA-G1 binds inhibitory receptors ILT2 and ILT4, inhibiting NK- and T-cell-mediated lysis of target cells. Secreted HLA-G5 binds CD8 and induces Fas/FasL-mediated apoptosis in activated CD8+ lymphocytes. Engaging KIR2DL4 triggers different reactions depending on the activation state of effector cells.","method":"In vitro receptor-binding and cytotoxicity assays; apoptosis assays with soluble HLA-G5 and CD8+ lymphocytes","journal":"Seminars in cancer biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — receptor binding and functional cytotoxicity/apoptosis assays, multiple receptor-ligand pairs examined, single lab","pmids":["14708711"],"is_preprint":false},{"year":2003,"finding":"HLA-G is expressed in the cornea (keratocytes, epithelial cells, and endothelial cells) of both healthy and pathologic tissue, with transcript splicing pattern consistent with other HLA-G-expressing tissues, suggesting a role in maintaining immune privilege of the cornea.","method":"Immunohistochemistry with anti-HLA-G monoclonal antibody; RT-PCR for HLA-G transcripts on cryopreserved corneal sections","journal":"Human immunology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — localization by IHC and RT-PCR without direct functional consequence demonstrated, single lab","pmids":["14602233"],"is_preprint":false},{"year":2005,"finding":"HLA-G gene silencing in tumor cells is caused by CpG site hypermethylation within a 450-bp 5' regulatory region upstream of the start codon, and activation upon demethylation correlates with histone acetylation status within this region and a putative locus control region at -1.2 kb.","method":"Bisulfite sequencing/methylation analysis of HLA-G 5' regulatory region in melanoma and choriocarcinoma cell lines; chromatin immunoprecipitation for histone acetylation; 5-aza-2'-deoxycytidine treatment","journal":"International journal of cancer","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — mechanistic epigenetic study combining bisulfite sequencing, ChIP for histone acetylation, and pharmacological demethylation, replicated finding from PNAS 2003 in additional cell models","pmids":["15514928"],"is_preprint":false},{"year":2005,"finding":"The HLA-G*0105N null allele, which has a single base deletion preventing translation of HLA-G1, HLA-G4, and HLA-G5, can generate alternative isoforms (HLA-G2, G3, G6, G7) that are expressed on the cell surface and retain the ability to protect against NK cell lysis.","method":"Cloning of genomic HLA-G*0105N DNA; transfection into HLA-class I-positive human cell line; NK cytotoxicity assay","journal":"Biology of reproduction","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct transfection and NK cytotoxicity assay, single lab, mechanistically informative about isoform function","pmids":["15814900"],"is_preprint":false},{"year":2006,"finding":"The crystal structure of HLA-G reveals a nine-residue self-peptide bound in a constrained mode within the peptide-binding cleft (similar to HLA-E). The α3 domain is structurally distinct from class Ia MHC molecules, providing a structural basis for observed differences in affinity for LIR-1 and LIR-2. A disulfide-bonded dimer adopts an oblique conformation suggesting a 1:2 (HLA-G dimer:receptor) complex stoichiometry, and the dimer orientation makes KIR2DL4 binding via dimerization unlikely.","method":"X-ray crystallography of HLA-G","journal":"Human immunology","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure determination with direct functional implications for receptor binding and dimer stoichiometry","pmids":["17400055"],"is_preprint":false},{"year":2007,"finding":"HLA-G expression on ovarian carcinoma cells (OVCAR-3 transfectants) directly inhibits NK-92 cell lysis, and this inhibition can be restored by the anti-HLA-G conformational monoclonal antibody 87G.","method":"HLA-G cloning and expression in OVCAR-3 cells; NK-92 cytotoxicity assay; antibody-blocking experiment with mAb 87G","journal":"Annals of oncology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct transfection/functional NK cytotoxicity assay with antibody-blocking control, single lab","pmids":["17846022"],"is_preprint":false},{"year":2007,"finding":"Soluble HLA-G1 (HLA-G5) inhibits endothelial cell proliferation, migration, and tubule formation through binding to the CD160 receptor via an apoptotic pathway, and blocks in vivo rabbit corneal neoangiogenesis.","method":"In vitro endothelial cell proliferation, migration and tubule formation assays with soluble HLA-G1; receptor binding to CD160; in vivo rabbit corneal angiogenesis model","journal":"Journal of reproductive immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro and in vivo functional assays with identified receptor (CD160), single lab","pmids":["17467060"],"is_preprint":false},{"year":2007,"finding":"HLA-G induces suppressor cells via two distinct processes: (i) differentiation of naïve T cells into lasting suppressor T cells, and (ii) rapid transfer of HLA-G from APCs or tumor cells to T or NK cells via trogocytosis, converting them into temporary HLA-G-positive suppressor cells. Tumor microenvironment factors including hypoxia, IDO, and TNF-α regulate HLA-G expression by tumor cells.","method":"In vitro T cell differentiation assays; trogocytosis experiments; hypoxia/IDO/TNF-α stimulation of tumor cells with HLA-G expression readout","journal":"Seminars in cancer biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple mechanistic experiments (trogocytosis, suppressor cell induction, microenvironmental regulation), single lab","pmids":["17881247"],"is_preprint":false},{"year":2009,"finding":"Progesterone upregulates HLA-G expression (both cell-surface and cytoplasmic) in mesenchymal stem cells (MSCs) isolated from adipose tissue, bone marrow, and decidua, at both protein and mRNA levels.","method":"MSC culture with progesterone; flow cytometry and RT-PCR for HLA-G expression","journal":"American journal of reproductive immunology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, single stimulation experiment with two readout methods but no mechanistic detail of transcriptional pathway","pmids":["19527229"],"is_preprint":false},{"year":2012,"finding":"miR-148a and miR-152 down-regulate HLA-G expression by directly binding its 3'UTR, and this down-regulation abolishes LILRB1 (ILT2)-mediated inhibition of NK cell killing. In placenta, both miRNAs are expressed at relatively low levels compared to other tissues, which may enable tissue-specific high HLA-G expression.","method":"miRNA overexpression/inhibition experiments; 3'UTR luciferase reporter assay; NK cell killing assay; LILRB1 recognition assay; miRNA and HLA-G mRNA expression profiling in placenta vs. other tissues","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — 3'UTR reporter assay demonstrating direct miRNA binding plus functional NK killing assay demonstrating downstream consequence, multiple orthogonal methods in one study","pmids":["22438923"],"is_preprint":false},{"year":2014,"finding":"KIR2DL4-HLA-G interaction induces cellular senescence in NK cells, and the resulting senescence-associated secretory phenotype (SASP) promotes secretion of pro-angiogenic factors that drive vascular remodeling during pregnancy.","method":"Review of experimental data on KIR2DL4-HLA-G interactions, NK cell senescence assays, and cytokine secretion readouts (senescence-associated secretory phenotype)","journal":"Cellular & molecular immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — review citing experimental evidence for KIR2DL4-HLA-G-induced NK senescence and SASP; mechanistic pathway well-described but this paper is a review rather than primary data","pmids":["24998350"],"is_preprint":false},{"year":2020,"finding":"Three distinct types of HLA-G+ extravillous trophoblasts (EVT) can be purified from the placental disk and chorionic membrane; these EVT subtypes have unique phenotypes, gene expression profiles, and differing capacities to induce regulatory T cells (Treg) in co-culture, with gestational age and fetal sex influencing EVT biology.","method":"Primary cell purification and culture of HLA-G+ EVT from term and first trimester placenta; phenotypic characterization by flow cytometry; gene expression profiling; Treg induction co-culture assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — primary cell purification with multiple functional readouts, single lab","pmids":["32581122"],"is_preprint":false},{"year":2021,"finding":"Anti-HLA-G CAR-T cells are cytotoxic against HLA-G+ tumor cells in vitro and can control and eliminate HLA-G+ tumors in vivo. These CAR-T cells are insensitive to ILT2-mediated inhibition by tumor-expressed HLA-G and differentiate into long-term memory effector cells without functional exhaustion upon repeated stimulation.","method":"Generation of third-generation CAR-T cells with anti-HLA-G monoclonal antibodies; in vitro cytotoxicity assays; in vivo tumor control experiments; ILT2-inhibition assays; memory phenotype analysis","journal":"Journal for immunotherapy of cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro and in vivo functional experiments with clear mechanistic readouts, single lab","pmids":["33737343"],"is_preprint":false}],"current_model":"HLA-G is a nonclassical MHC class Ib molecule produced by extravillous trophoblasts that exerts immune tolerance primarily by binding inhibitory receptors (ILT2, ILT4, KIR2DL4, CD160) on NK cells, T cells, and myeloid cells, thereby suppressing cytolysis and T-cell responses; its restricted expression is enforced by CpG methylation of its unique promoter (which lacks ISRE, NF-κB, and CIITA response elements), is upregulated by IFN-γ and progesterone and downregulated by miR-148a/miR-152 binding its 3'UTR, and is sustained at the cell surface by its short cytoplasmic tail that impairs endocytosis; structurally, HLA-G binds a constrained self-peptide and forms disulfide-bonded dimers that enable multivalent receptor engagement, while soluble HLA-G5 additionally induces CD8+ T-cell apoptosis via Fas/FasL and inhibits angiogenesis through CD160."},"narrative":{"mechanistic_narrative":"HLA-G is a nonclassical MHC class Ib molecule that establishes immune tolerance by delivering inhibitory signals to NK cells, T cells, and myeloid cells, a role first demonstrated when HLA-G expression rendered target cells resistant to lysis by decidual NK cells [PMID:8181068] and was extended to inhibition of allogeneic T-cell proliferation and antigen-specific CTL responses [PMID:10092545]. Tolerance is executed through engagement of inhibitory receptors: membrane-bound HLA-G1 binds ILT2 and ILT4 to suppress NK- and T-cell cytolysis, while secreted HLA-G5 binds CD8 to trigger Fas/FasL-mediated apoptosis of activated CD8+ lymphocytes, and engagement of KIR2DL4 produces context-dependent outcomes [PMID:14708711]; KIR2DL4 ligation can additionally drive NK senescence with a pro-angiogenic secretory phenotype supporting vascular remodeling [PMID:24998350]. Crystallographic analysis shows HLA-G binds a constrained nine-residue self-peptide and forms disulfide-bonded dimers in an oblique conformation consistent with a 1:2 dimer:receptor stoichiometry, providing the structural basis for differential LIR-1/LIR-2 affinity [PMID:17400055], and surface delivery of HLA-G1 and HLA-G5 requires peptide loading via TAP-dependent or TAP-independent routes [PMID:12440768]. Beyond immune inhibition, soluble HLA-G5 suppresses endothelial proliferation, migration, and angiogenesis through CD160 [PMID:17467060], and HLA-G expands tolerance by inducing durable suppressor T cells and by transferring itself to effector cells through trogocytosis [PMID:17881247]. Its restricted expression is enforced at multiple levels: a promoter that lacks the ISRE and carries modified enhancer A/SXY modules, making it unresponsive to NF-κB, IRF1, and CIITA [PMID:11797094]; CpG methylation of its 5' regulatory region that silences the gene and is reversible by demethylating agents and HDAC inhibitors [PMID:12552087, PMID:15514928]; and post-transcriptional repression by miR-148a/miR-152 binding the 3'UTR, which when relieved restores ILT2-mediated NK inhibition [PMID:22438923]. Inducible expression is driven by IFN-γ at the transcriptional level [PMID:8666791, PMID:11137212], while the short cytoplasmic tail impairs endocytosis and sustains surface display [PMID:9368631]. HLA-G is a physiological hallmark of extravillous trophoblasts whose subtypes differ in capacity to induce regulatory T cells [PMID:32581122], and its tolerogenic axis has been exploited therapeutically by anti-HLA-G CAR-T cells that resist ILT2-mediated inhibition by HLA-G+ tumors [PMID:33737343].","teleology":[{"year":1994,"claim":"Established that a nonclassical class I molecule, not classical HLA, can shield cells from NK-mediated killing, defining HLA-G's core tolerogenic function.","evidence":"NK cytotoxicity assay on HLA-G transfectants of HLA-null 721.221 cells against decidual and peripheral NK effectors","pmids":["8181068"],"confidence":"Medium","gaps":["Did not identify the inhibitory receptor mediating protection","Limited to NK cytolysis, not other immune effectors"]},{"year":1996,"claim":"Showed HLA-G is inducible rather than strictly constitutive, with IFN-γ selectively upregulating it in myeloid cells.","evidence":"Northern blot, RT-PCR, flow cytometry on macrophage lines and monocytes treated with interferons","pmids":["8666791"],"confidence":"Medium","gaps":["Did not map the cis-elements or transcription factors mediating IFN-γ response","Mechanism of IFN-γ specificity over IFN-α/β unresolved"]},{"year":1997,"claim":"Explained how HLA-G is retained at the cell surface, attributing impaired endocytosis to its short cytoplasmic tail.","evidence":"Flow cytometry endocytosis assay with chimeric HLA-C/HLA-G constructs and non-perturbative β2m label-exchange tracking","pmids":["9368631"],"confidence":"High","gaps":["Did not identify the trafficking machinery bypassed","Did not address differential trafficking of soluble vs membrane isoforms"]},{"year":1999,"claim":"Broadened HLA-G's inhibitory reach beyond NK cells to T-cell proliferation and CTL responses, and to a tumor (melanoma) context.","evidence":"In vitro NK and T-cell assays with HLA-G1/G2 transfectants and soluble HLA-G; NK assays with HLA-G+ melanoma lines","pmids":["10092545","10479054"],"confidence":"Medium","gaps":["Receptors mediating T-cell inhibition not yet defined","Distinction between membrane and soluble isoform mechanisms incomplete"]},{"year":2000,"claim":"Confirmed IFN-γ induction operates at the transcriptional level in primary epithelial tissues beyond myeloid cells.","evidence":"Flow cytometry and RT-PCR in primary thymic and amnion epithelial cells treated with IFN-γ","pmids":["11137212"],"confidence":"Medium","gaps":["Promoter elements responsible not mapped","No link to physiological signals driving induction in vivo"]},{"year":2001,"claim":"Defined the cis-regulatory basis of HLA-G's restricted expression, showing its promoter is refractory to canonical class I inducers.","evidence":"Promoter sequence analysis and transgenic HLA-G mouse models with in situ hybridization/RT-PCR","pmids":["11797094"],"confidence":"Medium","gaps":["Did not reconcile promoter unresponsiveness with documented IFN-γ inducibility","Positive activators driving tissue-specific expression not identified"]},{"year":2002,"claim":"Showed peptide loading is a quality-control checkpoint for surface delivery of both membrane and soluble HLA-G, using TAP-dependent and -independent routes.","evidence":"Biochemical trafficking studies using viral US-protein immune-escape tools","pmids":["12440768"],"confidence":"Medium","gaps":["Identity of bound peptides not defined here","TAP-independent loading mechanism not detailed"]},{"year":2003,"claim":"Identified the inhibitory receptor partners (ILT2, ILT4, CD8, KIR2DL4) and resolved that soluble HLA-G5 kills CD8+ cells via Fas/FasL.","evidence":"In vitro receptor-binding, cytotoxicity, and apoptosis assays with HLA-G isoforms","pmids":["14708711"],"confidence":"Medium","gaps":["KIR2DL4 outcome dependence on activation state not mechanistically resolved","Quantitative receptor affinities not established"]},{"year":2003,"claim":"Established DNA methylation as the dominant epigenetic switch silencing HLA-G, reversible to drive surface expression.","evidence":"5-aza-2'-deoxycytidine and HDAC-inhibitor treatment of seven HLA-G-negative lines with RT-PCR/flow cytometry; bisulfite sequencing and ChIP in melanoma/choriocarcinoma lines","pmids":["12552087","15514928"],"confidence":"High","gaps":["Did not identify methyltransferases/demethylases regulating the locus in vivo","Role of the putative -1.2 kb locus control region not functionally dissected"]},{"year":2005,"claim":"Demonstrated that truncated HLA-G isoforms from the G*0105N null allele retain surface expression and NK-protective function, expanding the functional repertoire beyond HLA-G1/G5.","evidence":"Transfection of genomic HLA-G*0105N and NK cytotoxicity assay","pmids":["15814900"],"confidence":"Medium","gaps":["Receptors engaged by alternative isoforms not defined","Physiological relevance in null-allele carriers not addressed"]},{"year":2006,"claim":"Provided the structural basis for HLA-G receptor selectivity, revealing a constrained self-peptide and a disulfide-bonded dimer implying 1:2 receptor stoichiometry.","evidence":"X-ray crystallography of HLA-G","pmids":["17400055"],"confidence":"High","gaps":["No co-crystal with ILT/KIR receptors","Dimer contribution to in vivo signaling not directly tested"]},{"year":2007,"claim":"Extended HLA-G function to anti-angiogenesis via CD160 and to active spread of tolerance through suppressor-cell induction and trogocytosis, with tumor microenvironment cues regulating its expression.","evidence":"Endothelial proliferation/migration/tubule and in vivo rabbit corneal angiogenesis assays; T-cell differentiation and trogocytosis assays; hypoxia/IDO/TNF-α stimulation; OVCAR-3 transfectant NK assays with mAb 87G blocking","pmids":["17467060","17881247","17846022"],"confidence":"Medium","gaps":["Mechanistic link between CD160 binding and endothelial apoptosis incomplete","Durability and in vivo relevance of trogocytosis-derived suppressors unclear"]},{"year":2012,"claim":"Identified post-transcriptional control by miR-148a/miR-152 and tied it functionally to NK inhibition, explaining tissue-specific high expression in placenta.","evidence":"miRNA gain/loss, 3'UTR luciferase reporter, NK killing and LILRB1 recognition assays, plus tissue miRNA profiling","pmids":["22438923"],"confidence":"High","gaps":["Upstream regulation of these miRNAs not addressed","Interaction with methylation-based control not integrated"]},{"year":2014,"claim":"Linked KIR2DL4-HLA-G engagement to NK senescence and a pro-angiogenic secretory phenotype supporting pregnancy vascular remodeling, expanding HLA-G beyond simple inhibition.","evidence":"Review of NK senescence assays and SASP cytokine secretion readouts from KIR2DL4-HLA-G studies","pmids":["24998350"],"confidence":"Medium","gaps":["Primary data summarized in a review, not original here","Signaling pathway from KIR2DL4 to senescence not detailed"]},{"year":2020,"claim":"Resolved heterogeneity among HLA-G+ extravillous trophoblasts, showing subtype-specific capacity to induce regulatory T cells in maternal-fetal tolerance.","evidence":"Primary EVT purification, phenotyping, gene expression profiling, and Treg induction co-cultures","pmids":["32581122"],"confidence":"Medium","gaps":["Molecular determinants of subtype Treg-inducing capacity not defined","Causal role of HLA-G itself in Treg induction not isolated from other EVT factors"]},{"year":2021,"claim":"Demonstrated therapeutic exploitation of the HLA-G axis with CAR-T cells that resist ILT2 inhibition and avoid exhaustion against HLA-G+ tumors.","evidence":"Anti-HLA-G CAR-T cytotoxicity, in vivo tumor control, ILT2-inhibition, and memory phenotype assays","pmids":["33737343"],"confidence":"Medium","gaps":["On-target/off-tumor effects in HLA-G+ healthy tissue not assessed","Clinical efficacy not established"]},{"year":null,"claim":"How the layered regulatory inputs (promoter architecture, CpG methylation, miRNAs, IFN-γ, progesterone) are integrated to produce the precise tissue- and context-specific expression of HLA-G remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model linking epigenetic, transcriptional, and post-transcriptional control","Positive transcriptional activators driving constitutive trophoblast expression unidentified","In vivo receptor-engagement stoichiometry and signaling outputs incompletely defined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[0,3,9]},{"term_id":"GO:0005198","term_label":"structural molecule activity","supporting_discovery_ids":[13]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[9,19]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[2,9,12]},{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[9,15]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[0,3,9,16]},{"term_id":"R-HSA-1500931","term_label":"Cell-Cell communication","supporting_discovery_ids":[9,16]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[9,15]}],"complexes":[],"partners":["LILRB1","LILRB2","KIR2DL4","CD160","CD8"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P17693","full_name":"HLA class I histocompatibility antigen, alpha chain G","aliases":["HLA G antigen","MHC class I antigen G"],"length_aa":338,"mass_kda":38.2,"function":"Non-classical major histocompatibility class Ib molecule involved in immune regulatory processes at the maternal-fetal interface (PubMed:19304799, PubMed:23184984, PubMed:29262349). In complex with B2M/beta-2 microglobulin binds a limited repertoire of nonamer self-peptides derived from intracellular proteins including histones and ribosomal proteins (PubMed:7584149, PubMed:8805247). Peptide-bound HLA-G-B2M complex acts as a ligand for inhibitory/activating KIR2DL4, LILRB1 and LILRB2 receptors on uterine immune cells to promote fetal development while maintaining maternal-fetal tolerance (PubMed:16366734, PubMed:19304799, PubMed:20448110, PubMed:23184984, PubMed:27859042, PubMed:29262349). Upon interaction with KIR2DL4 and LILRB1 receptors on decidual NK cells, it triggers NK cell senescence-associated secretory phenotype as a molecular switch to promote vascular remodeling and fetal growth in early pregnancy (PubMed:16366734, PubMed:19304799, PubMed:23184984, PubMed:29262349). Through interaction with KIR2DL4 receptor on decidual macrophages induces pro-inflammatory cytokine production mainly associated with tissue remodeling (PubMed:19304799). Through interaction with LILRB2 receptor triggers differentiation of type 1 regulatory T cells and myeloid-derived suppressor cells, both of which actively maintain maternal-fetal tolerance (PubMed:20448110, PubMed:27859042). May play a role in balancing tolerance and antiviral-immunity at maternal-fetal interface by keeping in check the effector functions of NK, CD8+ T cells and B cells (PubMed:10190900, PubMed:11290782, PubMed:24453251). Reprograms B cells toward an immune suppressive phenotype via LILRB1 (PubMed:24453251). May induce immune activation/suppression via intercellular membrane transfer (trogocytosis), likely enabling interaction with KIR2DL4, which resides mostly in endosomes (PubMed:20179272, PubMed:26460007). Through interaction with the inhibitory receptor CD160 on endothelial cells may control angiogenesis in immune privileged sites (PubMed:16809620) Likely does not bind B2M and presents peptides. Negatively regulates NK cell- and CD8+ T cell-mediated cytotoxicity (PubMed:11290782) Likely does not bind B2M and presents peptides. Negatively regulates NK cell- and CD8+ T cell-mediated cytotoxicity (PubMed:11290782) Likely does not bind B2M and presents peptides. Negatively regulates NK cell- and CD8+ T cell-mediated cytotoxicity (PubMed:11290782) Non-classical major histocompatibility class Ib molecule involved in immune regulatory processes at the maternal-fetal interface (PubMed:19304799, PubMed:23184984, PubMed:29262349). In complex with B2M/beta-2 microglobulin binds a limited repertoire of nonamer self-peptides derived from intracellular proteins including histones and ribosomal proteins (PubMed:7584149, PubMed:8805247). Peptide-bound HLA-G-B2M complex acts as a ligand for inhibitory/activating KIR2DL4, LILRB1 and LILRB2 receptors on uterine immune cells to promote fetal development while maintaining maternal-fetal tolerance (PubMed:16366734, PubMed:19304799, PubMed:20448110, PubMed:23184984, PubMed:29262349). Upon interaction with KIR2DL4 and LILRB1 receptors on decidual NK cells, it triggers NK cell senescence-associated secretory phenotype as a molecular switch to promote vascular remodeling and fetal growth in early pregnancy (PubMed:16366734, PubMed:19304799, PubMed:23184984, PubMed:29262349). Through interaction with KIR2DL4 receptor on decidual macrophages induces pro-inflammatory cytokine production mainly associated with tissue remodeling (PubMed:19304799). Through interaction with LILRB2 receptor triggers differentiation of type 1 regulatory T cells and myeloid-derived suppressor cells, both of which actively maintain maternal-fetal tolerance (PubMed:20448110). Reprograms B cells toward an immune suppressive phenotype via LILRB1 (PubMed:24453251) Likely does not bind B2M and presents peptides Likely does not bind B2M and presents peptides","subcellular_location":"Cell projection, filopodium membrane","url":"https://www.uniprot.org/uniprotkb/P17693/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/HLA-G","classification":"Not Classified","n_dependent_lines":3,"n_total_lines":1208,"dependency_fraction":0.0024834437086092716},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/HLA-G","total_profiled":1310},"omim":[{"mim_id":"614389","title":"PREGNANCY LOSS, RECURRENT, SUSCEPTIBILITY TO, 1; RPRGL1","url":"https://www.omim.org/entry/614389"},{"mim_id":"602619","title":"C-TERMINAL-BINDING PROTEIN 2; CTBP2","url":"https://www.omim.org/entry/602619"},{"mim_id":"602618","title":"C-TERMINAL-BINDING PROTEIN 1; CTBP1","url":"https://www.omim.org/entry/602618"},{"mim_id":"602209","title":"RAS-RESPONSIVE ELEMENT BINDING PROTEIN 1; RREB1","url":"https://www.omim.org/entry/602209"},{"mim_id":"600807","title":"ASTHMA, SUSCEPTIBILITY TO","url":"https://www.omim.org/entry/600807"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Group enriched","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"pituitary gland","ntpm":13.7},{"tissue":"placenta","ntpm":10.5}],"url":"https://www.proteinatlas.org/search/HLA-G"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"P17693","domains":[{"cath_id":"3.30.500.10","chopping":"25-203","consensus_level":"high","plddt":97.2472,"start":25,"end":203},{"cath_id":"2.60.40.10","chopping":"209-296","consensus_level":"high","plddt":95.3301,"start":209,"end":296}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P17693","model_url":"https://alphafold.ebi.ac.uk/files/AF-P17693-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P17693-F1-predicted_aligned_error_v6.png","plddt_mean":90.44},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=HLA-G","jax_strain_url":"https://www.jax.org/strain/search?query=HLA-G"},"sequence":{"accession":"P17693","fasta_url":"https://rest.uniprot.org/uniprotkb/P17693.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P17693/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P17693"}},"corpus_meta":[{"pmid":"15857883","id":"PMC_15857883","title":"HLA-G and immune tolerance in pregnancy.","date":"2005","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/15857883","citation_count":358,"is_preprint":false},{"pmid":"26073983","id":"PMC_26073983","title":"HLA-G: An Immune Checkpoint Molecule.","date":"2015","source":"Advances in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/26073983","citation_count":335,"is_preprint":false},{"pmid":"14711057","id":"PMC_14711057","title":"HLA-G molecules: from maternal-fetal tolerance to tissue acceptance.","date":"2003","source":"Advances in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/14711057","citation_count":267,"is_preprint":false},{"pmid":"21107637","id":"PMC_21107637","title":"Implications of the polymorphism of HLA-G on its function, regulation, evolution and disease association.","date":"2010","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/21107637","citation_count":261,"is_preprint":false},{"pmid":"16280356","id":"PMC_16280356","title":"HLA-G in human reproduction: aspects of genetics, function and pregnancy complications.","date":"2005","source":"Human reproduction update","url":"https://pubmed.ncbi.nlm.nih.gov/16280356","citation_count":227,"is_preprint":false},{"pmid":"14602233","id":"PMC_14602233","title":"Expression of HLA-G in human cornea, an immune-privileged tissue.","date":"2003","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/14602233","citation_count":213,"is_preprint":false},{"pmid":"28279591","id":"PMC_28279591","title":"HLA-G: At the Interface of Maternal-Fetal Tolerance.","date":"2017","source":"Trends in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/28279591","citation_count":211,"is_preprint":false},{"pmid":"8666791","id":"PMC_8666791","title":"Expression of HLA-G in human mononuclear phagocytes and selective induction by IFN-gamma.","date":"1996","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/8666791","citation_count":193,"is_preprint":false},{"pmid":"8181068","id":"PMC_8181068","title":"Resistance of HLA-G and HLA-A2 transfectants to lysis by decidual NK cells.","date":"1994","source":"Cellular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/8181068","citation_count":172,"is_preprint":false},{"pmid":"18538632","id":"PMC_18538632","title":"A critical look at HLA-G.","date":"2008","source":"Trends in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/18538632","citation_count":160,"is_preprint":false},{"pmid":"22537084","id":"PMC_22537084","title":"The immunosuppressive molecule HLA-G and its clinical implications.","date":"2012","source":"Critical reviews in clinical laboratory sciences","url":"https://pubmed.ncbi.nlm.nih.gov/22537084","citation_count":154,"is_preprint":false},{"pmid":"17825579","id":"PMC_17825579","title":"Soluble HLA-G: Are they clinically relevant?","date":"2007","source":"Seminars in cancer biology","url":"https://pubmed.ncbi.nlm.nih.gov/17825579","citation_count":147,"is_preprint":false},{"pmid":"10319265","id":"PMC_10319265","title":"The functionality of HLA-G is emerging.","date":"1999","source":"Immunological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/10319265","citation_count":143,"is_preprint":false},{"pmid":"24741620","id":"PMC_24741620","title":"Transcriptional and posttranscriptional regulations of the HLA-G gene.","date":"2014","source":"Journal of immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/24741620","citation_count":132,"is_preprint":false},{"pmid":"12552087","id":"PMC_12552087","title":"HLA-G gene repression is reversed by demethylation.","date":"2003","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12552087","citation_count":132,"is_preprint":false},{"pmid":"33193435","id":"PMC_33193435","title":"Roles of HLA-G in the Maternal-Fetal Immune Microenvironment.","date":"2020","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33193435","citation_count":128,"is_preprint":false},{"pmid":"22438923","id":"PMC_22438923","title":"MiRNA-mediated control of HLA-G expression and function.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22438923","citation_count":128,"is_preprint":false},{"pmid":"30319626","id":"PMC_30319626","title":"Heterogeneity of HLA-G Expression in Cancers: Facing the Challenges.","date":"2018","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30319626","citation_count":115,"is_preprint":false},{"pmid":"23897901","id":"PMC_23897901","title":"Molecular pathways: human leukocyte antigen G (HLA-G).","date":"2013","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/23897901","citation_count":100,"is_preprint":false},{"pmid":"25477881","id":"PMC_25477881","title":"HLA-G Molecules in Autoimmune Diseases and Infections.","date":"2014","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/25477881","citation_count":98,"is_preprint":false},{"pmid":"25143957","id":"PMC_25143957","title":"HLA-G as a tolerogenic molecule in transplantation and pregnancy.","date":"2014","source":"Journal of immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/25143957","citation_count":97,"is_preprint":false},{"pmid":"24800261","id":"PMC_24800261","title":"The dual role of HLA-G in cancer.","date":"2014","source":"Journal of immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/24800261","citation_count":95,"is_preprint":false},{"pmid":"19508383","id":"PMC_19508383","title":"Non-classical transcriptional regulation of HLA-G: an update.","date":"2009","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/19508383","citation_count":86,"is_preprint":false},{"pmid":"17881247","id":"PMC_17881247","title":"Expression of tolerogenic HLA-G molecules in cancer prevents antitumor responses.","date":"2007","source":"Seminars in cancer biology","url":"https://pubmed.ncbi.nlm.nih.gov/17881247","citation_count":85,"is_preprint":false},{"pmid":"24998350","id":"PMC_24998350","title":"HLA-G-mediated NK cell senescence promotes vascular remodeling: implications for reproduction.","date":"2014","source":"Cellular & molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/24998350","citation_count":82,"is_preprint":false},{"pmid":"24818168","id":"PMC_24818168","title":"Some basic aspects of HLA-G biology.","date":"2014","source":"Journal of immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/24818168","citation_count":80,"is_preprint":false},{"pmid":"34777357","id":"PMC_34777357","title":"HLA-G: An Important Mediator of Maternal-Fetal Immune-Tolerance.","date":"2021","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/34777357","citation_count":80,"is_preprint":false},{"pmid":"21960588","id":"PMC_21960588","title":"The tolerogenic interplay(s) among HLA-G, myeloid APCs, and regulatory cells.","date":"2011","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/21960588","citation_count":80,"is_preprint":false},{"pmid":"12547505","id":"PMC_12547505","title":"HLA-G and MIC expression in tumors and their role in anti-tumor immunity.","date":"2003","source":"Trends in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/12547505","citation_count":80,"is_preprint":false},{"pmid":"17846022","id":"PMC_17846022","title":"HLA-G expression in human ovarian carcinoma counteracts NK cell function.","date":"2007","source":"Annals of oncology : official journal of the European Society for Medical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/17846022","citation_count":80,"is_preprint":false},{"pmid":"21080028","id":"PMC_21080028","title":"The importance of HLA-G expression in embryos, trophoblast cells, and embryonic stem cells.","date":"2010","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/21080028","citation_count":79,"is_preprint":false},{"pmid":"11574277","id":"PMC_11574277","title":"HLA-G remains a mystery.","date":"2001","source":"Trends in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11574277","citation_count":76,"is_preprint":false},{"pmid":"32630545","id":"PMC_32630545","title":"HLA-G: A New Immune Checkpoint in Cancer?","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32630545","citation_count":74,"is_preprint":false},{"pmid":"11797094","id":"PMC_11797094","title":"HLA-G unique promoter region: functional implications.","date":"2001","source":"Immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/11797094","citation_count":71,"is_preprint":false},{"pmid":"34276691","id":"PMC_34276691","title":"HLA-G/ILTs Targeted Solid Cancer Immunotherapy: Opportunities and Challenges.","date":"2021","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/34276691","citation_count":70,"is_preprint":false},{"pmid":"24839609","id":"PMC_24839609","title":"Immunomodulatory properties of HLA-G in infectious diseases.","date":"2014","source":"Journal of immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/24839609","citation_count":70,"is_preprint":false},{"pmid":"10092545","id":"PMC_10092545","title":"The immunotolerance role of HLA-G.","date":"1999","source":"Seminars in cancer biology","url":"https://pubmed.ncbi.nlm.nih.gov/10092545","citation_count":69,"is_preprint":false},{"pmid":"16916651","id":"PMC_16916651","title":"Soluble HLA-G in rheumatoid arthritis.","date":"2006","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16916651","citation_count":68,"is_preprint":false},{"pmid":"9430736","id":"PMC_9430736","title":"HLA-G polymorphisms: neutral evolution or novel function?","date":"1997","source":"Journal of reproductive immunology","url":"https://pubmed.ncbi.nlm.nih.gov/9430736","citation_count":67,"is_preprint":false},{"pmid":"12492704","id":"PMC_12492704","title":"HLA-G in transplantation: a relevant molecule for inhibition of graft rejection?","date":"2003","source":"American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons","url":"https://pubmed.ncbi.nlm.nih.gov/12492704","citation_count":67,"is_preprint":false},{"pmid":"10225437","id":"PMC_10225437","title":"Expression of HLA G in human tumors is not a frequent event.","date":"1999","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/10225437","citation_count":66,"is_preprint":false},{"pmid":"14708711","id":"PMC_14708711","title":"HLA-G modulates immune responses by diverse receptor interactions.","date":"2003","source":"Seminars in cancer biology","url":"https://pubmed.ncbi.nlm.nih.gov/14708711","citation_count":65,"is_preprint":false},{"pmid":"24860568","id":"PMC_24860568","title":"Controlling the Immunological Crosstalk during Conception and Pregnancy: HLA-G in Reproduction.","date":"2014","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/24860568","citation_count":65,"is_preprint":false},{"pmid":"12896824","id":"PMC_12896824","title":"HLA-G, pre-eclampsia, immunity and vascular events.","date":"2003","source":"Journal of reproductive immunology","url":"https://pubmed.ncbi.nlm.nih.gov/12896824","citation_count":65,"is_preprint":false},{"pmid":"25132109","id":"PMC_25132109","title":"New insights into HLA-G mediated tolerance.","date":"2014","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/25132109","citation_count":64,"is_preprint":false},{"pmid":"17118165","id":"PMC_17118165","title":"The role of HLA-G in human pregnancy.","date":"2006","source":"Reproductive biology and endocrinology : RB&E","url":"https://pubmed.ncbi.nlm.nih.gov/17118165","citation_count":63,"is_preprint":false},{"pmid":"32922387","id":"PMC_32922387","title":"HLA-G Neo-Expression on Tumors.","date":"2020","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32922387","citation_count":61,"is_preprint":false},{"pmid":"20434034","id":"PMC_20434034","title":"HLA-G and immune evasion in cancer cells.","date":"2010","source":"Journal of the Formosan Medical Association = Taiwan yi zhi","url":"https://pubmed.ncbi.nlm.nih.gov/20434034","citation_count":61,"is_preprint":false},{"pmid":"19570712","id":"PMC_19570712","title":"HLA-G: a human pregnancy-related immunomodulator.","date":"2009","source":"Current opinion in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/19570712","citation_count":61,"is_preprint":false},{"pmid":"35154112","id":"PMC_35154112","title":"HLA-G: Too Much or Too Little? Role in Cancer and Autoimmune Disease.","date":"2022","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35154112","citation_count":60,"is_preprint":false},{"pmid":"21080027","id":"PMC_21080027","title":"Emerging topics and new perspectives on HLA-G.","date":"2010","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/21080027","citation_count":60,"is_preprint":false},{"pmid":"11137212","id":"PMC_11137212","title":"Modulation of HLA-G expression in human thymic and amniotic epithelial cells.","date":"2000","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11137212","citation_count":59,"is_preprint":false},{"pmid":"21116680","id":"PMC_21116680","title":"The role of HLA-G in immunity and hematopoiesis.","date":"2010","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/21116680","citation_count":55,"is_preprint":false},{"pmid":"9619769","id":"PMC_9619769","title":"HLA-G polymorphisms and allele frequencies in Caucasians.","date":"1998","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/9619769","citation_count":55,"is_preprint":false},{"pmid":"15514928","id":"PMC_15514928","title":"HLA-G gene activation in tumor cells involves cis-acting epigenetic changes.","date":"2005","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/15514928","citation_count":55,"is_preprint":false},{"pmid":"10479054","id":"PMC_10479054","title":"HLA-G expression in human melanoma cells: protection from NK cytolysis.","date":"1999","source":"Journal of reproductive immunology","url":"https://pubmed.ncbi.nlm.nih.gov/10479054","citation_count":53,"is_preprint":false},{"pmid":"21248264","id":"PMC_21248264","title":"HLA-G expression in human embryonic stem cells and preimplantation embryos.","date":"2011","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/21248264","citation_count":52,"is_preprint":false},{"pmid":"32581122","id":"PMC_32581122","title":"Three types of HLA-G+ extravillous trophoblasts that have distinct immune regulatory properties.","date":"2020","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/32581122","citation_count":52,"is_preprint":false},{"pmid":"17400055","id":"PMC_17400055","title":"Structural studies on HLA-G: implications for ligand and receptor binding.","date":"2006","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/17400055","citation_count":51,"is_preprint":false},{"pmid":"17400059","id":"PMC_17400059","title":"HLA-G expression is a fundamental prerequisite to pregnancy.","date":"2006","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/17400059","citation_count":51,"is_preprint":false},{"pmid":"25772038","id":"PMC_25772038","title":"Biology of the immunomodulatory molecule HLA-G in human liver diseases.","date":"2015","source":"Journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/25772038","citation_count":50,"is_preprint":false},{"pmid":"17629722","id":"PMC_17629722","title":"HLA-G and its role in implantation (review).","date":"2007","source":"Journal of assisted reproduction and genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17629722","citation_count":49,"is_preprint":false},{"pmid":"16214086","id":"PMC_16214086","title":"Immuno-tolerogenic functions of HLA-G: relevance in transplantation and oncology.","date":"2005","source":"Autoimmunity reviews","url":"https://pubmed.ncbi.nlm.nih.gov/16214086","citation_count":49,"is_preprint":false},{"pmid":"32733439","id":"PMC_32733439","title":"HLA-G Genotype/Expression/Disease Association Studies: Success, Hurdles, and Perspectives.","date":"2020","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32733439","citation_count":48,"is_preprint":false},{"pmid":"9368631","id":"PMC_9368631","title":"Impaired spontaneous endocytosis of HLA-G.","date":"1997","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/9368631","citation_count":48,"is_preprint":false},{"pmid":"18691135","id":"PMC_18691135","title":"HLA-G and inflammatory diseases.","date":"2008","source":"Inflammation & allergy drug targets","url":"https://pubmed.ncbi.nlm.nih.gov/18691135","citation_count":47,"is_preprint":false},{"pmid":"14708718","id":"PMC_14708718","title":"HLA-G and lymphoproliferative disorders.","date":"2003","source":"Seminars in cancer biology","url":"https://pubmed.ncbi.nlm.nih.gov/14708718","citation_count":46,"is_preprint":false},{"pmid":"21103908","id":"PMC_21103908","title":"HLA-G in organ transplantation: towards clinical applications.","date":"2010","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/21103908","citation_count":45,"is_preprint":false},{"pmid":"21459722","id":"PMC_21459722","title":"Expression of HLA-G in patients with hepatocellular carcinoma.","date":"2011","source":"Hepatobiliary & pancreatic diseases international : HBPD INT","url":"https://pubmed.ncbi.nlm.nih.gov/21459722","citation_count":45,"is_preprint":false},{"pmid":"17467060","id":"PMC_17467060","title":"Soluble HLA-G and control of angiogenesis.","date":"2007","source":"Journal of reproductive immunology","url":"https://pubmed.ncbi.nlm.nih.gov/17467060","citation_count":44,"is_preprint":false},{"pmid":"19531101","id":"PMC_19531101","title":"Characterization of HLA-G expression in renal cell carcinoma.","date":"2009","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/19531101","citation_count":44,"is_preprint":false},{"pmid":"33737343","id":"PMC_33737343","title":"First immunotherapeutic CAR-T cells against the immune checkpoint protein HLA-G.","date":"2021","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/33737343","citation_count":42,"is_preprint":false},{"pmid":"15814900","id":"PMC_15814900","title":"HLA-G*0105N null allele encodes functional HLA-G isoforms.","date":"2005","source":"Biology of reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/15814900","citation_count":40,"is_preprint":false},{"pmid":"36768880","id":"PMC_36768880","title":"HLA-G and Recurrent Pregnancy Loss.","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36768880","citation_count":39,"is_preprint":false},{"pmid":"17681474","id":"PMC_17681474","title":"Clinical and biological significance of HLA-G expression in ovarian cancer.","date":"2007","source":"Seminars in cancer biology","url":"https://pubmed.ncbi.nlm.nih.gov/17681474","citation_count":39,"is_preprint":false},{"pmid":"11216872","id":"PMC_11216872","title":"HLA-G expression by tumors.","date":"2001","source":"American journal of reproductive immunology (New York, N.Y. : 1989)","url":"https://pubmed.ncbi.nlm.nih.gov/11216872","citation_count":38,"is_preprint":false},{"pmid":"31489189","id":"PMC_31489189","title":"Intercellular transfer of HLA-G: its potential in cancer immunology.","date":"2019","source":"Clinical & translational immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31489189","citation_count":38,"is_preprint":false},{"pmid":"19527229","id":"PMC_19527229","title":"HLA-G expression is up-regulated by progesterone in mesenchymal stem cells.","date":"2009","source":"American journal of reproductive immunology (New York, N.Y. : 1989)","url":"https://pubmed.ncbi.nlm.nih.gov/19527229","citation_count":37,"is_preprint":false},{"pmid":"35237271","id":"PMC_35237271","title":"Role of HLA-G in Viral Infections.","date":"2022","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35237271","citation_count":35,"is_preprint":false},{"pmid":"32680723","id":"PMC_32680723","title":"Fetal HLA-G mediated immune tolerance and interferon response in preeclampsia.","date":"2020","source":"EBioMedicine","url":"https://pubmed.ncbi.nlm.nih.gov/32680723","citation_count":35,"is_preprint":false},{"pmid":"38310272","id":"PMC_38310272","title":"Harnessing the potential of HLA-G in cancer therapy: advances, challenges, and prospects.","date":"2024","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38310272","citation_count":34,"is_preprint":false},{"pmid":"20356631","id":"PMC_20356631","title":"Interaction between HLA-G and monocyte/macrophages in human pregnancy.","date":"2010","source":"Journal of reproductive immunology","url":"https://pubmed.ncbi.nlm.nih.gov/20356631","citation_count":34,"is_preprint":false},{"pmid":"10092548","id":"PMC_10092548","title":"HLA-G expression: immune privilege for tumour cells?","date":"1999","source":"Seminars in cancer biology","url":"https://pubmed.ncbi.nlm.nih.gov/10092548","citation_count":34,"is_preprint":false},{"pmid":"21376476","id":"PMC_21376476","title":"HLA-G and pregnancy adverse outcomes.","date":"2011","source":"Medical hypotheses","url":"https://pubmed.ncbi.nlm.nih.gov/21376476","citation_count":34,"is_preprint":false},{"pmid":"10092551","id":"PMC_10092551","title":"The regulation of HLA class I expression: is HLA-G the odd one out?","date":"1999","source":"Seminars in cancer biology","url":"https://pubmed.ncbi.nlm.nih.gov/10092551","citation_count":34,"is_preprint":false},{"pmid":"17689098","id":"PMC_17689098","title":"HLA-G expression in malignant melanoma.","date":"2007","source":"Seminars in cancer biology","url":"https://pubmed.ncbi.nlm.nih.gov/17689098","citation_count":33,"is_preprint":false},{"pmid":"35328349","id":"PMC_35328349","title":"HLA-G and Other Immune Checkpoint Molecules as Targets for Novel Combined Immunotherapies.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35328349","citation_count":33,"is_preprint":false},{"pmid":"10228553","id":"PMC_10228553","title":"Immunotolerant functions of HLA-G.","date":"1999","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/10228553","citation_count":33,"is_preprint":false},{"pmid":"10816129","id":"PMC_10816129","title":"HLA-G in the human placenta: expression and potential functions.","date":"2000","source":"Biochemical Society transactions","url":"https://pubmed.ncbi.nlm.nih.gov/10816129","citation_count":33,"is_preprint":false},{"pmid":"22931388","id":"PMC_22931388","title":"New insights into HLA-G and inflammatory diseases.","date":"2012","source":"Inflammation & allergy drug targets","url":"https://pubmed.ncbi.nlm.nih.gov/22931388","citation_count":33,"is_preprint":false},{"pmid":"33745758","id":"PMC_33745758","title":"Role of the HLA-G immune checkpoint molecule in pregnancy.","date":"2021","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33745758","citation_count":31,"is_preprint":false},{"pmid":"35185887","id":"PMC_35185887","title":"Roles of HLA-G/KIR2DL4 in Breast Cancer Immune Microenvironment.","date":"2022","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35185887","citation_count":30,"is_preprint":false},{"pmid":"11137217","id":"PMC_11137217","title":"Analysis of the role of HLA-G in preeclampsia.","date":"2000","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11137217","citation_count":30,"is_preprint":false},{"pmid":"16330473","id":"PMC_16330473","title":"Does 'soluble' HLA-G really exist? Another twist to the tale.","date":"2005","source":"Molecular human reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/16330473","citation_count":30,"is_preprint":false},{"pmid":"31558330","id":"PMC_31558330","title":"A role for both HLA-F and HLA-G in reproduction and during pregnancy?","date":"2019","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31558330","citation_count":29,"is_preprint":false},{"pmid":"17707652","id":"PMC_17707652","title":"Structure, expression and function of HLA-G in renal cell carcinoma.","date":"2007","source":"Seminars in cancer biology","url":"https://pubmed.ncbi.nlm.nih.gov/17707652","citation_count":28,"is_preprint":false},{"pmid":"32670296","id":"PMC_32670296","title":"The Role of HLA-G in Human Papillomavirus Infections and Cervical Carcinogenesis.","date":"2020","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32670296","citation_count":28,"is_preprint":false},{"pmid":"10831130","id":"PMC_10831130","title":"HLA-G polymorphisms and molecule function--questions and more questions--a review.","date":"2000","source":"Placenta","url":"https://pubmed.ncbi.nlm.nih.gov/10831130","citation_count":27,"is_preprint":false},{"pmid":"12440768","id":"PMC_12440768","title":"HLA-G protein processing and transport to the cell surface.","date":"2002","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/12440768","citation_count":26,"is_preprint":false},{"pmid":"37627278","id":"PMC_37627278","title":"The Molecular Mechanisms of HLA-G Regulatory Function on Immune Cells during Early Pregnancy.","date":"2023","source":"Biomolecules","url":"https://pubmed.ncbi.nlm.nih.gov/37627278","citation_count":26,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":38207,"output_tokens":5462,"usd":0.098276,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":13997,"output_tokens":5378,"usd":0.102218,"stage2_stop_reason":"end_turn"},"total_usd":0.200494,"stage1_batch_id":"msgbatch_01DUPACZi7AAWwuZiUjseQF4","stage2_batch_id":"msgbatch_018yt7chE3f48PEFtDwtj6AE","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1994,\n      \"finding\": \"HLA-G expression on trophoblast cells confers resistance to lysis by decidual NK cells. HLA-G transfectants of HLA-null LCL 721.221 cells were protected from NK effectors isolated from decidua or peripheral blood, demonstrating that a nonclassical Class I HLA molecule provides NK resistance.\",\n      \"method\": \"NK cytotoxicity assay using HLA-G transfectants of HLA-null LCL 721.221 cells\",\n      \"journal\": \"Cellular immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct functional transfection experiment with cytotoxicity readout, single lab but clear mechanistic demonstration\",\n      \"pmids\": [\"8181068\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"IFN-γ selectively induces HLA-G expression in mononuclear phagocytes (macrophage cell lines and blood monocytes) at both mRNA and protein levels, increasing cell-surface and intracellular HLA-G in a dose-dependent manner, whereas IFN-α and IFN-β are poor inducers of cell-surface HLA-G protein.\",\n      \"method\": \"Northern blot hybridization, RT-PCR, immunohistochemistry, flow cytometry on macrophage cell lines (U937, HL-60, THP-1) and blood monocytes treated with interferons\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (RT-PCR, Northern blot, flow cytometry), single lab\",\n      \"pmids\": [\"8666791\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"HLA-G undergoes severely impaired spontaneous endocytosis compared to classical MHC class I proteins, attributable to its short cytoplasmic tail. Chimeric proteins with HLA-C extracellular domains fused to the HLA-G C-terminal sequence, or GPI-tailed HLA-C proteins, were also not efficiently internalized, confirming the cytoplasmic tail as the determinant.\",\n      \"method\": \"Flow cytometry-based endocytosis assay using antibody-labeled transfectants; mutant β2-microglobulin (Ser88Cys) fluorescent-label exchange method to track internalization non-perturbatively\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple orthogonal methods including a non-perturbative fluorescent label exchange approach, chimeric protein controls directly attributing phenotype to cytoplasmic tail\",\n      \"pmids\": [\"9368631\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"HLA-G inhibits NK cell cytolysis and T cell allogeneic proliferative and antigen-specific CTL responses. Membrane-bound HLA-G1 and HLA-G2 transfected cells, as well as full-length soluble HLA-G, were shown to impair NK and T cell functions in vitro.\",\n      \"method\": \"In vitro NK cytotoxicity assays and T cell allogeneic proliferation/CTL assays using HLA-G1- and HLA-G2-transfected cells and soluble HLA-G protein\",\n      \"journal\": \"Seminars in cancer biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct functional assays with transfected cells and soluble protein, single lab, multiple immune cell types tested\",\n      \"pmids\": [\"10092545\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"HLA-G expressed on melanoma cells inhibits NK cell cytolysis. HLA-G-positive melanoma cell lines inhibited lysis by the NK cell line YT2C2-PR, and this inhibition occurred through interaction with inhibitory receptors distinct from known KIRs recognizing HLA-E or classical class I molecules.\",\n      \"method\": \"RT-PCR for HLA-G transcripts in melanoma cell lines and biopsies; NK cytotoxicity assay using YT2C2-PR NK cells against HLA-G-positive melanoma lines\",\n      \"journal\": \"Journal of reproductive immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct NK cytotoxicity assay with natural HLA-G-expressing tumor cells, single lab\",\n      \"pmids\": [\"10479054\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"IFN-γ re-induces HLA-G cell surface expression and upregulates HLA-G transcripts in primary thymic epithelial cell (TEC) and amnion epithelial cell cultures, demonstrating that IFN-γ induction is mediated at the transcriptional level in these tissues.\",\n      \"method\": \"Flow cytometry for HLA-G surface expression; RT-PCR for HLA-G transcripts in primary thymic and amnion epithelial cell cultures treated with IFN-γ\",\n      \"journal\": \"Human immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple methods (flow cytometry, RT-PCR) in primary cell cultures, single lab\",\n      \"pmids\": [\"11137212\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"The HLA-G promoter lacks the ISRE element and contains modified enhancer A and SXY modules, rendering it unresponsive to NF-κB, IRF1, and class II transactivator (CIITA) DNA-binding factors, explaining its restricted tissue-specific expression.\",\n      \"method\": \"Promoter sequence analysis; transgenic HLA-G mouse models with in situ hybridization and RT-PCR to assess constitutive placental expression\",\n      \"journal\": \"Immunogenetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional promoter dissection with transgenic mouse in vivo validation, single lab analysis\",\n      \"pmids\": [\"11797094\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Membrane-bound HLA-G1 and soluble HLA-G5 both require peptide association for cell surface expression, utilizing TAP-dependent or TAP-independent pathways. Peptide loading plays a critical role in controlling the quality of HLA-G molecules reaching the cell surface. Surface expression of truncated HLA-G isoforms is also possible.\",\n      \"method\": \"Biochemical trafficking studies and analysis of viral immune escape strategies (US proteins); biochemical fractionation and protein expression analysis\",\n      \"journal\": \"Cellular and molecular life sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — biochemical characterization of intracellular trafficking using viral escape mutants as tools, single lab\",\n      \"pmids\": [\"12440768\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"HLA-G gene repression is mediated by DNA methylation of CpG sites in its 5' regulatory region. Treatment of HLA-G-negative cell lines with histone deacetylase inhibitors or the demethylating agent 5-aza-2'-deoxycytidine reverses this repression and can directly induce HLA-G cell-surface expression.\",\n      \"method\": \"Pharmacological demethylation (5-aza-2'-deoxycytidine) and histone deacetylase inhibitor treatment of seven HLA-G-negative cell lines; RT-PCR and flow cytometry for HLA-G expression\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — mechanistic epigenetic experiment with two orthogonal pharmacological approaches across multiple cell lines, direct functional readout of cell-surface expression\",\n      \"pmids\": [\"12552087\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"HLA-G1 binds inhibitory receptors ILT2 and ILT4, inhibiting NK- and T-cell-mediated lysis of target cells. Secreted HLA-G5 binds CD8 and induces Fas/FasL-mediated apoptosis in activated CD8+ lymphocytes. Engaging KIR2DL4 triggers different reactions depending on the activation state of effector cells.\",\n      \"method\": \"In vitro receptor-binding and cytotoxicity assays; apoptosis assays with soluble HLA-G5 and CD8+ lymphocytes\",\n      \"journal\": \"Seminars in cancer biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — receptor binding and functional cytotoxicity/apoptosis assays, multiple receptor-ligand pairs examined, single lab\",\n      \"pmids\": [\"14708711\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"HLA-G is expressed in the cornea (keratocytes, epithelial cells, and endothelial cells) of both healthy and pathologic tissue, with transcript splicing pattern consistent with other HLA-G-expressing tissues, suggesting a role in maintaining immune privilege of the cornea.\",\n      \"method\": \"Immunohistochemistry with anti-HLA-G monoclonal antibody; RT-PCR for HLA-G transcripts on cryopreserved corneal sections\",\n      \"journal\": \"Human immunology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — localization by IHC and RT-PCR without direct functional consequence demonstrated, single lab\",\n      \"pmids\": [\"14602233\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"HLA-G gene silencing in tumor cells is caused by CpG site hypermethylation within a 450-bp 5' regulatory region upstream of the start codon, and activation upon demethylation correlates with histone acetylation status within this region and a putative locus control region at -1.2 kb.\",\n      \"method\": \"Bisulfite sequencing/methylation analysis of HLA-G 5' regulatory region in melanoma and choriocarcinoma cell lines; chromatin immunoprecipitation for histone acetylation; 5-aza-2'-deoxycytidine treatment\",\n      \"journal\": \"International journal of cancer\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — mechanistic epigenetic study combining bisulfite sequencing, ChIP for histone acetylation, and pharmacological demethylation, replicated finding from PNAS 2003 in additional cell models\",\n      \"pmids\": [\"15514928\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"The HLA-G*0105N null allele, which has a single base deletion preventing translation of HLA-G1, HLA-G4, and HLA-G5, can generate alternative isoforms (HLA-G2, G3, G6, G7) that are expressed on the cell surface and retain the ability to protect against NK cell lysis.\",\n      \"method\": \"Cloning of genomic HLA-G*0105N DNA; transfection into HLA-class I-positive human cell line; NK cytotoxicity assay\",\n      \"journal\": \"Biology of reproduction\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct transfection and NK cytotoxicity assay, single lab, mechanistically informative about isoform function\",\n      \"pmids\": [\"15814900\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"The crystal structure of HLA-G reveals a nine-residue self-peptide bound in a constrained mode within the peptide-binding cleft (similar to HLA-E). The α3 domain is structurally distinct from class Ia MHC molecules, providing a structural basis for observed differences in affinity for LIR-1 and LIR-2. A disulfide-bonded dimer adopts an oblique conformation suggesting a 1:2 (HLA-G dimer:receptor) complex stoichiometry, and the dimer orientation makes KIR2DL4 binding via dimerization unlikely.\",\n      \"method\": \"X-ray crystallography of HLA-G\",\n      \"journal\": \"Human immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure determination with direct functional implications for receptor binding and dimer stoichiometry\",\n      \"pmids\": [\"17400055\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"HLA-G expression on ovarian carcinoma cells (OVCAR-3 transfectants) directly inhibits NK-92 cell lysis, and this inhibition can be restored by the anti-HLA-G conformational monoclonal antibody 87G.\",\n      \"method\": \"HLA-G cloning and expression in OVCAR-3 cells; NK-92 cytotoxicity assay; antibody-blocking experiment with mAb 87G\",\n      \"journal\": \"Annals of oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct transfection/functional NK cytotoxicity assay with antibody-blocking control, single lab\",\n      \"pmids\": [\"17846022\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Soluble HLA-G1 (HLA-G5) inhibits endothelial cell proliferation, migration, and tubule formation through binding to the CD160 receptor via an apoptotic pathway, and blocks in vivo rabbit corneal neoangiogenesis.\",\n      \"method\": \"In vitro endothelial cell proliferation, migration and tubule formation assays with soluble HLA-G1; receptor binding to CD160; in vivo rabbit corneal angiogenesis model\",\n      \"journal\": \"Journal of reproductive immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro and in vivo functional assays with identified receptor (CD160), single lab\",\n      \"pmids\": [\"17467060\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"HLA-G induces suppressor cells via two distinct processes: (i) differentiation of naïve T cells into lasting suppressor T cells, and (ii) rapid transfer of HLA-G from APCs or tumor cells to T or NK cells via trogocytosis, converting them into temporary HLA-G-positive suppressor cells. Tumor microenvironment factors including hypoxia, IDO, and TNF-α regulate HLA-G expression by tumor cells.\",\n      \"method\": \"In vitro T cell differentiation assays; trogocytosis experiments; hypoxia/IDO/TNF-α stimulation of tumor cells with HLA-G expression readout\",\n      \"journal\": \"Seminars in cancer biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple mechanistic experiments (trogocytosis, suppressor cell induction, microenvironmental regulation), single lab\",\n      \"pmids\": [\"17881247\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Progesterone upregulates HLA-G expression (both cell-surface and cytoplasmic) in mesenchymal stem cells (MSCs) isolated from adipose tissue, bone marrow, and decidua, at both protein and mRNA levels.\",\n      \"method\": \"MSC culture with progesterone; flow cytometry and RT-PCR for HLA-G expression\",\n      \"journal\": \"American journal of reproductive immunology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, single stimulation experiment with two readout methods but no mechanistic detail of transcriptional pathway\",\n      \"pmids\": [\"19527229\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"miR-148a and miR-152 down-regulate HLA-G expression by directly binding its 3'UTR, and this down-regulation abolishes LILRB1 (ILT2)-mediated inhibition of NK cell killing. In placenta, both miRNAs are expressed at relatively low levels compared to other tissues, which may enable tissue-specific high HLA-G expression.\",\n      \"method\": \"miRNA overexpression/inhibition experiments; 3'UTR luciferase reporter assay; NK cell killing assay; LILRB1 recognition assay; miRNA and HLA-G mRNA expression profiling in placenta vs. other tissues\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — 3'UTR reporter assay demonstrating direct miRNA binding plus functional NK killing assay demonstrating downstream consequence, multiple orthogonal methods in one study\",\n      \"pmids\": [\"22438923\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"KIR2DL4-HLA-G interaction induces cellular senescence in NK cells, and the resulting senescence-associated secretory phenotype (SASP) promotes secretion of pro-angiogenic factors that drive vascular remodeling during pregnancy.\",\n      \"method\": \"Review of experimental data on KIR2DL4-HLA-G interactions, NK cell senescence assays, and cytokine secretion readouts (senescence-associated secretory phenotype)\",\n      \"journal\": \"Cellular & molecular immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — review citing experimental evidence for KIR2DL4-HLA-G-induced NK senescence and SASP; mechanistic pathway well-described but this paper is a review rather than primary data\",\n      \"pmids\": [\"24998350\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Three distinct types of HLA-G+ extravillous trophoblasts (EVT) can be purified from the placental disk and chorionic membrane; these EVT subtypes have unique phenotypes, gene expression profiles, and differing capacities to induce regulatory T cells (Treg) in co-culture, with gestational age and fetal sex influencing EVT biology.\",\n      \"method\": \"Primary cell purification and culture of HLA-G+ EVT from term and first trimester placenta; phenotypic characterization by flow cytometry; gene expression profiling; Treg induction co-culture assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — primary cell purification with multiple functional readouts, single lab\",\n      \"pmids\": [\"32581122\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Anti-HLA-G CAR-T cells are cytotoxic against HLA-G+ tumor cells in vitro and can control and eliminate HLA-G+ tumors in vivo. These CAR-T cells are insensitive to ILT2-mediated inhibition by tumor-expressed HLA-G and differentiate into long-term memory effector cells without functional exhaustion upon repeated stimulation.\",\n      \"method\": \"Generation of third-generation CAR-T cells with anti-HLA-G monoclonal antibodies; in vitro cytotoxicity assays; in vivo tumor control experiments; ILT2-inhibition assays; memory phenotype analysis\",\n      \"journal\": \"Journal for immunotherapy of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro and in vivo functional experiments with clear mechanistic readouts, single lab\",\n      \"pmids\": [\"33737343\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"HLA-G is a nonclassical MHC class Ib molecule produced by extravillous trophoblasts that exerts immune tolerance primarily by binding inhibitory receptors (ILT2, ILT4, KIR2DL4, CD160) on NK cells, T cells, and myeloid cells, thereby suppressing cytolysis and T-cell responses; its restricted expression is enforced by CpG methylation of its unique promoter (which lacks ISRE, NF-κB, and CIITA response elements), is upregulated by IFN-γ and progesterone and downregulated by miR-148a/miR-152 binding its 3'UTR, and is sustained at the cell surface by its short cytoplasmic tail that impairs endocytosis; structurally, HLA-G binds a constrained self-peptide and forms disulfide-bonded dimers that enable multivalent receptor engagement, while soluble HLA-G5 additionally induces CD8+ T-cell apoptosis via Fas/FasL and inhibits angiogenesis through CD160.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"HLA-G is a nonclassical MHC class Ib molecule that establishes immune tolerance by delivering inhibitory signals to NK cells, T cells, and myeloid cells, a role first demonstrated when HLA-G expression rendered target cells resistant to lysis by decidual NK cells [#0] and was extended to inhibition of allogeneic T-cell proliferation and antigen-specific CTL responses [#3]. Tolerance is executed through engagement of inhibitory receptors: membrane-bound HLA-G1 binds ILT2 and ILT4 to suppress NK- and T-cell cytolysis, while secreted HLA-G5 binds CD8 to trigger Fas/FasL-mediated apoptosis of activated CD8+ lymphocytes, and engagement of KIR2DL4 produces context-dependent outcomes [#9]; KIR2DL4 ligation can additionally drive NK senescence with a pro-angiogenic secretory phenotype supporting vascular remodeling [#19]. Crystallographic analysis shows HLA-G binds a constrained nine-residue self-peptide and forms disulfide-bonded dimers in an oblique conformation consistent with a 1:2 dimer:receptor stoichiometry, providing the structural basis for differential LIR-1/LIR-2 affinity [#13], and surface delivery of HLA-G1 and HLA-G5 requires peptide loading via TAP-dependent or TAP-independent routes [#7]. Beyond immune inhibition, soluble HLA-G5 suppresses endothelial proliferation, migration, and angiogenesis through CD160 [#15], and HLA-G expands tolerance by inducing durable suppressor T cells and by transferring itself to effector cells through trogocytosis [#16]. Its restricted expression is enforced at multiple levels: a promoter that lacks the ISRE and carries modified enhancer A/SXY modules, making it unresponsive to NF-\\u03baB, IRF1, and CIITA [#6]; CpG methylation of its 5' regulatory region that silences the gene and is reversible by demethylating agents and HDAC inhibitors [#8, #11]; and post-transcriptional repression by miR-148a/miR-152 binding the 3'UTR, which when relieved restores ILT2-mediated NK inhibition [#18]. Inducible expression is driven by IFN-\\u03b3 at the transcriptional level [#1, #5], while the short cytoplasmic tail impairs endocytosis and sustains surface display [#2]. HLA-G is a physiological hallmark of extravillous trophoblasts whose subtypes differ in capacity to induce regulatory T cells [#20], and its tolerogenic axis has been exploited therapeutically by anti-HLA-G CAR-T cells that resist ILT2-mediated inhibition by HLA-G+ tumors [#21].\",\n  \"teleology\": [\n    {\n      \"year\": 1994,\n      \"claim\": \"Established that a nonclassical class I molecule, not classical HLA, can shield cells from NK-mediated killing, defining HLA-G's core tolerogenic function.\",\n      \"evidence\": \"NK cytotoxicity assay on HLA-G transfectants of HLA-null 721.221 cells against decidual and peripheral NK effectors\",\n      \"pmids\": [\"8181068\"],\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Did not identify the inhibitory receptor mediating protection\", \"Limited to NK cytolysis, not other immune effectors\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Showed HLA-G is inducible rather than strictly constitutive, with IFN-\\u03b3 selectively upregulating it in myeloid cells.\",\n      \"evidence\": \"Northern blot, RT-PCR, flow cytometry on macrophage lines and monocytes treated with interferons\",\n      \"pmids\": [\"8666791\"],\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Did not map the cis-elements or transcription factors mediating IFN-\\u03b3 response\", \"Mechanism of IFN-\\u03b3 specificity over IFN-\\u03b1/\\u03b2 unresolved\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Explained how HLA-G is retained at the cell surface, attributing impaired endocytosis to its short cytoplasmic tail.\",\n      \"evidence\": \"Flow cytometry endocytosis assay with chimeric HLA-C/HLA-G constructs and non-perturbative \\u03b22m label-exchange tracking\",\n      \"pmids\": [\"9368631\"],\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Did not identify the trafficking machinery bypassed\", \"Did not address differential trafficking of soluble vs membrane isoforms\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Broadened HLA-G's inhibitory reach beyond NK cells to T-cell proliferation and CTL responses, and to a tumor (melanoma) context.\",\n      \"evidence\": \"In vitro NK and T-cell assays with HLA-G1/G2 transfectants and soluble HLA-G; NK assays with HLA-G+ melanoma lines\",\n      \"pmids\": [\"10092545\", \"10479054\"],\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Receptors mediating T-cell inhibition not yet defined\", \"Distinction between membrane and soluble isoform mechanisms incomplete\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Confirmed IFN-\\u03b3 induction operates at the transcriptional level in primary epithelial tissues beyond myeloid cells.\",\n      \"evidence\": \"Flow cytometry and RT-PCR in primary thymic and amnion epithelial cells treated with IFN-\\u03b3\",\n      \"pmids\": [\"11137212\"],\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Promoter elements responsible not mapped\", \"No link to physiological signals driving induction in vivo\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Defined the cis-regulatory basis of HLA-G's restricted expression, showing its promoter is refractory to canonical class I inducers.\",\n      \"evidence\": \"Promoter sequence analysis and transgenic HLA-G mouse models with in situ hybridization/RT-PCR\",\n      \"pmids\": [\"11797094\"],\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Did not reconcile promoter unresponsiveness with documented IFN-\\u03b3 inducibility\", \"Positive activators driving tissue-specific expression not identified\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Showed peptide loading is a quality-control checkpoint for surface delivery of both membrane and soluble HLA-G, using TAP-dependent and -independent routes.\",\n      \"evidence\": \"Biochemical trafficking studies using viral US-protein immune-escape tools\",\n      \"pmids\": [\"12440768\"],\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Identity of bound peptides not defined here\", \"TAP-independent loading mechanism not detailed\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Identified the inhibitory receptor partners (ILT2, ILT4, CD8, KIR2DL4) and resolved that soluble HLA-G5 kills CD8+ cells via Fas/FasL.\",\n      \"evidence\": \"In vitro receptor-binding, cytotoxicity, and apoptosis assays with HLA-G isoforms\",\n      \"pmids\": [\"14708711\"],\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"KIR2DL4 outcome dependence on activation state not mechanistically resolved\", \"Quantitative receptor affinities not established\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Established DNA methylation as the dominant epigenetic switch silencing HLA-G, reversible to drive surface expression.\",\n      \"evidence\": \"5-aza-2'-deoxycytidine and HDAC-inhibitor treatment of seven HLA-G-negative lines with RT-PCR/flow cytometry; bisulfite sequencing and ChIP in melanoma/choriocarcinoma lines\",\n      \"pmids\": [\"12552087\", \"15514928\"],\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Did not identify methyltransferases/demethylases regulating the locus in vivo\", \"Role of the putative -1.2 kb locus control region not functionally dissected\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Demonstrated that truncated HLA-G isoforms from the G*0105N null allele retain surface expression and NK-protective function, expanding the functional repertoire beyond HLA-G1/G5.\",\n      \"evidence\": \"Transfection of genomic HLA-G*0105N and NK cytotoxicity assay\",\n      \"pmids\": [\"15814900\"],\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Receptors engaged by alternative isoforms not defined\", \"Physiological relevance in null-allele carriers not addressed\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Provided the structural basis for HLA-G receptor selectivity, revealing a constrained self-peptide and a disulfide-bonded dimer implying 1:2 receptor stoichiometry.\",\n      \"evidence\": \"X-ray crystallography of HLA-G\",\n      \"pmids\": [\"17400055\"],\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"No co-crystal with ILT/KIR receptors\", \"Dimer contribution to in vivo signaling not directly tested\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Extended HLA-G function to anti-angiogenesis via CD160 and to active spread of tolerance through suppressor-cell induction and trogocytosis, with tumor microenvironment cues regulating its expression.\",\n      \"evidence\": \"Endothelial proliferation/migration/tubule and in vivo rabbit corneal angiogenesis assays; T-cell differentiation and trogocytosis assays; hypoxia/IDO/TNF-\\u03b1 stimulation; OVCAR-3 transfectant NK assays with mAb 87G blocking\",\n      \"pmids\": [\"17467060\", \"17881247\", \"17846022\"],\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Mechanistic link between CD160 binding and endothelial apoptosis incomplete\", \"Durability and in vivo relevance of trogocytosis-derived suppressors unclear\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Identified post-transcriptional control by miR-148a/miR-152 and tied it functionally to NK inhibition, explaining tissue-specific high expression in placenta.\",\n      \"evidence\": \"miRNA gain/loss, 3'UTR luciferase reporter, NK killing and LILRB1 recognition assays, plus tissue miRNA profiling\",\n      \"pmids\": [\"22438923\"],\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Upstream regulation of these miRNAs not addressed\", \"Interaction with methylation-based control not integrated\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Linked KIR2DL4-HLA-G engagement to NK senescence and a pro-angiogenic secretory phenotype supporting pregnancy vascular remodeling, expanding HLA-G beyond simple inhibition.\",\n      \"evidence\": \"Review of NK senescence assays and SASP cytokine secretion readouts from KIR2DL4-HLA-G studies\",\n      \"pmids\": [\"24998350\"],\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Primary data summarized in a review, not original here\", \"Signaling pathway from KIR2DL4 to senescence not detailed\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Resolved heterogeneity among HLA-G+ extravillous trophoblasts, showing subtype-specific capacity to induce regulatory T cells in maternal-fetal tolerance.\",\n      \"evidence\": \"Primary EVT purification, phenotyping, gene expression profiling, and Treg induction co-cultures\",\n      \"pmids\": [\"32581122\"],\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Molecular determinants of subtype Treg-inducing capacity not defined\", \"Causal role of HLA-G itself in Treg induction not isolated from other EVT factors\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Demonstrated therapeutic exploitation of the HLA-G axis with CAR-T cells that resist ILT2 inhibition and avoid exhaustion against HLA-G+ tumors.\",\n      \"evidence\": \"Anti-HLA-G CAR-T cytotoxicity, in vivo tumor control, ILT2-inhibition, and memory phenotype assays\",\n      \"pmids\": [\"33737343\"],\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"On-target/off-tumor effects in HLA-G+ healthy tissue not assessed\", \"Clinical efficacy not established\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the layered regulatory inputs (promoter architecture, CpG methylation, miRNAs, IFN-\\u03b3, progesterone) are integrated to produce the precise tissue- and context-specific expression of HLA-G remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"No unified model linking epigenetic, transcriptional, and post-transcriptional control\", \"Positive transcriptional activators driving constitutive trophoblast expression unidentified\", \"In vivo receptor-engagement stoichiometry and signaling outputs incompletely defined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 3, 9]},\n      {\"term_id\": \"GO:0005198\", \"supporting_discovery_ids\": [13]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [9, 19]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [2, 9, 12]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [9, 15]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 3, 9, 16]},\n      {\"term_id\": \"R-HSA-1500931\", \"supporting_discovery_ids\": [9, 16]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [9, 15]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"LILRB1\", \"LILRB2\", \"KIR2DL4\", \"CD160\", \"CD8\"],\n    \"other_free_text\": []\n  }\n}\n```","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}